Better Health for All

Hikma's core business is dedicated to putting better health within reach, treating 262 million patients in 2024

by focusing on high-quality, accessible medicines for chronic illnesses. The company reported over 10,900 cases with regulatory authorities globally in 2024, resulting in an adverse event rate of approximately 41.6 per million patients treated. Hikma invested 4.5% of its Group core revenue in R&D. It has achieved a 17% reduction in Scope 1 and 2 GHG emissions since its 2020 baseline. The company actively addresses the opioid epidemic by manufacturing overdose reversal medicines and treatments, donating over 600,000 doses of naloxone in the last three years, and partnering for access and awareness. Hikma provides substantial mental health support through internal employee initiatives and an external Mental Health Program in schools, impacting over 7,700 students. It also conducts extensive health education initiatives, including disease awareness campaigns reaching over 2 million individuals and a Healthy Schools Program.

Fair Trade & Ethical Sourcing

Hikma Pharmaceuticals reported zero substantiated cases of modern slavery, forced, or child labour in 2023

and 2024. The Supplier Code of Conduct, launched in 2022 and applying to all suppliers, partners, and third parties, contractually binds them to uphold ethical standards, including compliance with modern slavery and human trafficking prohibitions. The company identified 3.7% of its total 2024 spend on categories identified as high-risk materials, with corrective action plans issued for some suppliers and others under assessment. Between 2021 and 2024, Hikma maintained an average of 59%-60% spend on local suppliers.

Kind to Animals

Hikma's animal testing policy states that testing is conducted when required by regulatory authorities for new drug development.

When necessary, the company is committed to humane and ethical treatment, outsourcing to partners with the highest ethical standards. This commitment is guided by the "three Rs" principle: Replacement, Reduction, and Refinement. The company expects its suppliers to seek opportunities to replace or avoid animal use in research by using methods such as literature and analytical methods , and to use alternatives whenever scientifically valid and acceptable to regulators.

No War, No Weapons

In 2024, Hikma Pharmaceuticals PLC's core revenue was $3,156 million

. The company made $4.1 million in medicine donations and $3.9 million in charitable donations, totaling $8.0 million , which represents approximately 0.25% of its revenue. The company is a pharmaceutical firm with no evidence of defense-related business activities; its Corporate Responsibility and Ethics Committee (CREC) oversees business integrity, compliance, and ethical conduct . Hikma has a Supplier Code of Conduct requiring compliance with ethical standards, including those related to forced labor and human trafficking . In 2024, it assessed suppliers representing 60% of its procurement spend against labor and human rights , identifying 30 high-risk services suppliers in high-risk jurisdictions , issuing corrective action plans to 5 and keeping 9 under assessment . No substantiated cases of modern slavery, health and safety, or employment law violations were received in 2024 . The company has been a signatory to the United Nations Global Compact since 2007 , committing to its principles. In 2024, 98% of employees completed ethics and compliance training .

Planet-Friendly Business

Hikma Pharmaceuticals' target to reduce Scope 1 and 2 GHG emissions by 25% by 2030 from a 2020 baseline is stated to be in line with the Paris Climate Agreement’s well-below 2°C scenario

, but it is not explicitly stated as SBTi-validated. In 2024, 19.08% of the company's total electricity consumption was sourced from renewable energy, including expanded on-site solar capacity and green electricity in European facilities. The company reported one minor environmental compliance violation, incurring a $4,400 fine from the Ohio EPA in 2025 for hazardous waste. Hikma is partially aligned with TCFD recommendations, fully aligned to nine and partially to two. In 2024, 29.60% of its water extraction was from high water-stressed countries, with targeted mitigation strategies in place. The company engages with suppliers representing just over 55% of its Scope 3 emissions footprint or annual procurement spend for environmental criteria. The company has a climate justice initiative providing access to clean water for families in Egypt.